Evaluating the Effect of Melatonin on Pain Control and Quality of Life in Patients with Chronic Low Back Pain: A Randomized Clinical Trial
Novelty in Biomedicine,
Vol. 7 No. 3 (2019),
1 May 2019
,
Page 134-141
https://doi.org/10.22037/nbm.v7i3.23691
Abstract
Background: Almost everyone experiences low back pain at some point in his or her lives. Low back pain is becoming more prevalent in low-income and middle-income countries much more rapidly than in high-income countries. The objective of this study was to evaluate the effect of melatonin on pain control and quality of life in patients with chronic low back pain.Materials and Methods: Sixty patients with low back pain aged 45 and 75 years, with a history of back pain more for than 12 weeks and visual analogue scale (VAS) score more than three, who were referred to pain clinics of Akhtar Hospitals (Tehran, Iran) during June to August 2018. Patients were randomly assigned to one of the melatonin or control groups. Control group received diclofenac sodium 25mg tablet two or three times daily and the experimental or melatonin group, in addition to receiving diclofenac sodium 25mg tablet twice a day, received melatonin tablet (3mg) 30 to 40 minutes before bedtime for four weeks. Before the beginning of the study, at the end of the fourth week, both groups underwent VAS test and the levels of IL-1β and TNF-α were measured in these groups and they were asked to complete the quality of life questionnaire. Analysis of the data done by using covariance and Shapiro-Wilk tests through SPSS 22.
Results: Melatonin consumption reduced the pain and level of IL-1β and TNF-α in the experimental group compared to the control group (p<0.05). However, use of melatonin did not have a significant effect on quality of life (p>0.05).
Conclusion: In general, it can be stated that use of melatonin, in addition to reducing the pain, reduces the anti-inflammatory factors in patients with chronic low back pain. Based on the results of this study, melatonin can be recommended as a supplement for treatment of chronic low back pain.
- Affective symptoms
- Antipain
- Low back pain
- Quality of life
- Adult
How to Cite
References
Yazdi-Ravandi S, Taslimi Z, Saberi H, Shams J, Osanlo S, Nori G, et al. The role of resilience and age on quality of life in patients with pain disorders. Basic and clinical neuroscience. 2013; 4(1):24.
Pomares FB, Creac’h C, Faillenot I, Convers P, Peyron R. How a clock can change your pain? The illusion of duration and pain perception. PAIN. 2011;152(1):230-4.
Kovacs FM, Abraira V, Zamora J, del Real MTG, Llobera J, Fernández C. Correlation between pain, disability, and quality of life in patients with common low back pain. Spine. 2004;29(2):206-10.
Carlsson H, Rasmussen-Barr E. Clinical screening tests for assessing movement control in non-specific low-back pain. A systematic review of intra-and inter-observer reliability studies. Manual therapy. 2013;18(2):103-10.
O’Sullivan P. Diagnosis and classification of chronic low back pain disorders: maladaptive movement and motor control impairments as underlying mechanism. Manual therapy. 2005;10(4):242-55.
Waddell G, Schoene M. The back pain revolution: Elsevier Health Sciences; 2004.
Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep medicine reviews. 2005;9(1):25-39.
Mantovani M, Pértile R, Calixto JB, Santos AR, Rodrigues ALS. Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: evidence for involvement of N-methyl-D-aspartate receptors and the L-arginine-nitric oxide pathway. Neuroscience letters. 2003;343(1):1-4.
Boutin JA, Audinot V, Ferry G, Delagrange P. Molecular tools to study melatonin pathways and actions. Trends in Pharmacological sciences. 2005;26(8):412-9.
Tomás‐Zapico C, Coto‐Montes A. A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. Journal of pineal research. 2005;39(2):99-104.
Almay BG, von Knorring L, Wetterberg L. Melatonin in serum and urine in patients with idiopathic pain syndromes. Psychiatry research. 1987;22(3):179-91.
Golombek DA, Escolar E, Burin LJ, Sánchez MGDB, Cardinali DP. Time-dependent melatonin analgesia in mice: inhibition by opiate or benzodiazepine antagonism. European journal of pharmacology. 1991;194(1):25-30.
Yu C-X, Zhu C-B, Xu S-F, Cao X-D, Wu G-C. The analgesic effects of peripheral and central administration of melatonin in rats. European journal of pharmacology. 2000;403(1-2):49-53.
Zurowski D, Nowak L, Machowska A, Wordliczek J, Thor P. Exogenous melatonin abolishes mechanical allodynia but not thermal hyperalgesia in neuropathic pain. The role of the opioid system and benzodiazepine-gabaergic mechanism. J Physiol Pharmacol. 2012;63(6):641-7.
Ambriz-Tututi M, Granados-Soto V. Oral and spinal melatonin reduces tactile allodynia in rats via activation of MT2 and opioid receptors. Pain. 2007;132(3):273-80.
El-Shenawy SM, Abdel-Salam OM, Baiuomy AR, El-Batran S, Arbid MS. Studies on the anti-inflammatory and anti-nociceptive effects of melatonin in the rat. Pharmacological research. 2002;46(3):235-43.
Mayo JC, Sainz RM, Tan D-X, Hardeland R, Leon J, Rodriguez C, et al. Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. Journal of neuroimmunology. 2005;165(1-2):139-49.
Zimmermann M. Pathobiology of neuropathic pain. European journal of pharmacology. 2001;429(1-3):23-37.
Wu F-S, Yang Y-C, Tsai J-J. Melatonin potentiates the GABAA receptor-mediated current in cultured chick spinal cord neurons. Neuroscience letters. 1999;260(3):177-80.
- Abstract Viewed: 216 times
- PDF Downloaded: 132 times